x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BioBiz Buzz

https://biobizbuzz.com/

BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.Disclaimerhttps://biobizbuzz.com/disclaimer/

news news commentary

All Episodes

25:09

19. From Genesis to Revelations: Winners & Losers in...

BioBiz Buzz ·

2025/12/18

2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, fresh from his opening keynote at One Nucleus's landmark Genesis conference in London. Join us as Mike dissects the winners and losers reshaping pharma's landscape: Eli Lilly's historic as...

en-gb

22:44

18. Putting solid tumours under the T-knife: how a...

BioBiz Buzz ·

2025/12/16

Engineered T-cell receptor (TCR) therapies promise to do for solid tumours what chimeric antigen receptor T-cell (CAR-T) therapies have done for haematological malignancies. The two approaches are conceptually similar – each involves the isolation and modification of patients’ T-cells to recognise and kill tumour cells. The main difference lies in the types of antigens they can recognise. Whereas CAR-T therapies are currently confined to a handful of extracellular antigens expressed on the su...

en-gb

27:46

17. Democratizing Drug Discovery: How Lilly ExploR&D...

BioBiz Buzz ·

2025/12/03

The traditional biotech funding model hasn't fundamentally changed in decades: brilliant founders with promising science face an impossible choice; build expensive internal R&D capabilities or negotiate partnerships on terms controlled by Big Pharma. Tom Hopkins, VP and Head of Lilly ExploR&D, is working to flip that script. In this episode, Tom joins your host Mike Ward to discuss the four critical barriers early-stage biotechs face (expertise gaps, data infrastructure challeng...

en-gb

25:02

16. The Smart Money Talks: Inside Sofinnova's Bold...

BioBiz Buzz ·

2025/11/17

In a fundraising environment marked by cautious institutional investors, tightening belts, and widespread scepticism about early-stage venture capital, Sofinnova Partners has just closed its flagship Capital XI fund at €650 million, significantly exceeding its initial target of €500 million. What does this signal about the state of healthcare innovation funding in 2025? In this episode of BioBiz Buzz, your host Mike Ward sits down with Antoine Papiernik, Managing Partner and Chairman of Sofin...

en-gb

31:47

15. Targeting Misfolded SOD1 in ALS: A First-in-Class...

BioBiz Buzz ·

2025/11/11

This episode of BioBiz Buzz explores AL-S Pharma's pioneering approach to treating amyotrophic lateral sclerosis through AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1 protein. Host Mike Ward speaks with Dr. Michael Salzmann, CEO of AL-S Pharma and COO of Neurimmune, and Professor Angela Genge, CMO of AL-S Pharma and Professor of Neurology at McGill University. The conversation examines the devastating impact of ALS, a progressive neurodegenerative disease that typicall...

en-gb

17:21

14. The NanoPortal platform: Vivani Medical is...

BioBiz Buzz ·

2025/10/30

GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a significant challenge. US-based Vivani Medical, a clinical-stage biopharmaceutical company, is developing miniature implants which are designed to solve this problem. Once inserted, patients and caregivers can be confident that the intended medicine is being delivered throughout the once- or twice-yearly dosing...

en-gb

31:51

13. Tackling the undruggable: How Beactica's protein...

BioBiz Buzz ·

2025/10/23

Targeted protein degradation (TPD) represents one of the most transformative advances in drug discovery, with the global market projected to expand from USD 641 million in 2025 to as much as USD 9.85 billion by 2035. This rapidly evolving field enables researchers to eliminate disease-causing proteins rather than merely inhibiting their function, offering unprecedented opportunities to tackle previously "undruggable" targets that have eluded conventional therapeutic approaches with the ...

en-gb

19:54

12. Revolution technology set to transform breast...

BioBiz Buzz ·

2025/10/15

Breast cancer affects women of all ages after puberty in every country. In 2022, the disease struck an estimated 2.3 million women and claimed 670 000 lives globally, according to the World Health Organization. The Global Breast Cancer Initiative (GBCI), is working to reduce breast cancer deaths by 2.5% each year, preventing 2.5 million deaths by 2040. Early accurate diagnosis and effective treatment are key to achieving this. In this episode of Biobiz Buzz, your host Shani Alexander is joine...

en-gb

26:14

11. A technological breakthrough in the diagnosis of...

BioBiz Buzz ·

2025/10/09

AI-based software solutions are increasingly being used as a second pair of eyes to help clinicians with the early diagnosis of diseases. With skin cancer seeing increasing rates of incidence and mortality, software solutions hold the key to helping clinicians with timely diagnosis. In this episode of BioBiz Buzz, your host Shani Alexander sits down with Christoffer Ekström, CEO of AI Medical Technology, a Swedish-based company which has developed the Dermalyser, a diagnostic decision support...

en-gb

26:26

10. How Bioxodes is using tick saliva to create an...

BioBiz Buzz ·

2025/09/25

In a disease where hope has been scarce for decades, Belgian biotech Bioxodes is rewriting the rules of stroke treatment. Join your host Mike Ward in conversation with CEO Marc Dechamps as he reveals how his team transformed an unlikely discovery from tick saliva into BIOX-101, a first-in-class candidate therapeutic that could revolutionize care for intracerebral hemorrhage (ICH) patients. With no approved treatments available for ICH, a devastating condition that claims nearly 50% of patient...

en-gb

26:33

9. Beyond Billion-Dollar Bets: How Affibody Might...

BioBiz Buzz ·

2025/09/09

The radioligand therapy market will be worth $42 billion by 2032. However, beneath the headline-grabbing acquisitions lies a complex web of technical and commercial challenges that threaten to limit patient access to these revolutionary cancer treatments. The path to successful radioligand development is fraught with obstacles, from the "melting ice cube" logistics of short-lived radioisotopes to the renal toxicity pitfalls that plague small-molecule approaches. In this episode of BioBiz Buzz...

en-gb

19:40

8. Revolutionizing Cancer Drug Development with AI:...

BioBiz Buzz ·

2025/09/01

By 2040, the World Health Organization predicts that one in two people will be diagnosed with cancer in their lifetime. Yet the traditional pharmaceutical industry remains trapped in a devastating cycle: developing next-generation cancer drugs typically takes years, costs up to $2.5 billion, and often fails to deliver effective treatments to desperate patients. But what if there was a revolutionary way to shatter these constraints? In this episode of BioBiz Buzz, your host Mike Ward sits down...

en-gb

28:24

7. Exploring new possibilities in reproductive medicine

BioBiz Buzz ·

2025/08/29

ReproNovo demonstrated continued investor interest in the area of reproductive medicine by closing a $65 million Series A round earlier this year. In this episode, ReproNovo’s CEO and co-founder Jean Duvall joins your host, Cormac Sheridan, to discuss the company’s development strategy and how it put together the financing deal. ReproNovo is not a typical Series A company. It has secured rights to two clinical-stage assets that originated in large pharma companies. Novartis originally develop...

en-gb

29:44

6. Device Intelligence: How AI and Data Are Powering...

BioBiz Buzz ·

2025/07/17

In this episode of BioBiz Buzz, your host Shani Alexander is joined by Werner Lanthaler, founder and CEO of WLan Holding, to chart the seismic transformation underway in medical technology. Discover how the convergence of multi-omic diagnostics, AI-driven sensors, and smart implants is creating unprecedented value, from AI-enhanced stethoscopes that detect early heart murmurs to wearable devices that predict disease trajectories. Werner explains why platform-based approaches, combining ...

en-gb

21:18

5. Breaking New Ground in Pain Management with...

BioBiz Buzz ·

2025/07/03

As the opioid crisis continues to devastate communities worldwide, millions suffering from chronic and neuropathic pain face a critical dilemma: enduring debilitating pain or risking addiction with traditional opioid medications. In this episode of BioBiz Buzz, host Mike Ward explores one of modern medicine's most pressing challenges with Per von Mentzer, CEO of PharmNovo, a pioneering Swedish biotech company developing revolutionary non-addictive pain treatments. The conversation delve...

en-gb

26:01

The Power of International Alliances: Unpacking the...

BioBiz Buzz ·

2025/05/14

In 2024, despite a challenging global financial climate, Switzerland’s biotech sector showed remarkable resilience, maintaining steady revenues of CHF 7.2 billion while achieving a 22% increase in capital investment. In this episode of BioBiz Buzz, host Mike Ward interviews Michael Altorfer, CEO of the Swiss Biotech Association, to discuss the findings and implications of the Swiss Biotech Report 2025. The conversation focuses on the report’s central theme, "The Power of International Allianc...

en-gb

23:29

Rewriting the Future of Rare Cardiovascular Disease...

BioBiz Buzz ·

2025/05/02

In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics. Cereno’s lead candidates, CS1 and CS014, leverage epigenetic modulation through histone deacetylase inhibition (HDACi) to address the root causes of diseases like pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), aiming to reverse pa...

en-gb

14:23

Breaking Barriers in Sexual Health: Dicot Pharma’s...

BioBiz Buzz ·

2025/05/02

This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide. Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative drug candidate, LIB-01. Unlike conventional therapies, LIB-01 introduces a novel mechanism of action and offers a significantly longer efficacy window, 28 days after a brief 3-day dosing accor...

en-gb

19:54

CRISPR Unleashed: How Caszyme Is Redefining the...

BioBiz Buzz ·

2025/05/01

This episode of BioBiz Buzz features Dr. Monika Paule, CEO and co-founder of Caszyme, a pioneering Lithuanian biotech company at the forefront of CRISPR-Cas technology. Your host Mike Ward explores how Caszyme is expanding the boundaries of gene editing through novel enzyme discovery, delivery optimization, and strategic collaborations, enabling breakthroughs in therapeutics, diagnostics, and sustainable agriculture. Dr. Paule discusses Caszyme’s unique approach to engineering sma...

en-gb

19 results

Similar Podcasts

Expres Ráno

Expres FM

PBS News Hour - Full Show

PBS News

CD Voice

China Daily

Israel Today: Ongoing War Report

Noa Levi

Jeffrey Epstein: The Coverup Chronicles

Bobby Capucci